Brief Intervention for OCD Fears
| Status: | Suspended |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 12/2/2018 |
| Start Date: | June 2016 |
| End Date: | June 2019 |
The study will test the efficacy of propranolol or placebo, administered after reactivation
of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and
avoidance in OCD.
of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and
avoidance in OCD.
Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline
assessments of fear and avoidance. Participants will be randomly assigned to a single dose of
propranolol 40mg or placebo, administered immediately after a fear reactivation procedure.
Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral
avoidance task 2 weeks after the intervention
assessments of fear and avoidance. Participants will be randomly assigned to a single dose of
propranolol 40mg or placebo, administered immediately after a fear reactivation procedure.
Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral
avoidance task 2 weeks after the intervention
Inclusion Criteria:
- Principal Diagnosis of Obsessive-Compulsive Disorder
Exclusion Criteria:
- History of other serious psychiatric disorder
- Current Major Depressive Disorder
- Women who are pregnant or nursing
- Current use of psychiatric medication
- Persons planning to start another treatment during the study period
- Any significant medical condition that might increase the risk or participation or use
of medications that might negatively interact with propranolol
We found this trial at
1
site
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
